Education
About Us
Working with TipRanks
Follow Us
Compugen Ltd (CGEN)
NASDAQ:CGEN
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.06Last Year’s EPS
-0.02Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 19, 2025
|% Change Since: 4.32%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a strategic shift in leadership, strong financial health, and promising clinical advancements, particularly with AstraZeneca. However, revenue decline and challenges in the TIGIT space were noted.Company Guidance
During Compugen's First Quarter 2025 Results Conference Call, key guidance was provided regarding the company's future plans and ongoing projects. The company is focusing on advancing its clinical immuno-oncology pipeline, particularly the anti-PVRIG antibody COM701, with a sub-trial in ovarian cancer expected to share interim analysis in the second half of 2026. There is a noted emphasis on achieving a three-month improvement in progression-free survival over placebo. Compugen also highlighted the potential commercial opportunity with AstraZeneca's rilvegostomig, targeting over $5 billion in peak year revenues. Financially, Compugen reported a cash balance of $103.7 million as of March 31, 2025, and a net loss of $7.2 million for the quarter, maintaining a cash runway into 2027. The call underscored the company's strategic plans to capitalize on its innovative pipeline in the coming years.Leadership Transition and Strategic Vision
Anat Cohen-Dayag announced her transition to Executive Chair, with Eran Ophir taking over as CEO. This change aims to build on a robust foundation and ensure growth, with a cash runway secured until 2027.
Advancements in Clinical Trials
Initiation of a sub-trial for COM701 in ovarian cancer, targeting an unmet medical need. This is part of a broader strategy to advance immuno-oncology pipeline.
Strategic Collaborations with AstraZeneca
AstraZeneca's initiation of multiple Phase 3 trials using the TIGIT component derived from COM902, with potential for substantial commercial opportunity and future milestone payments and royalties for Compugen.
Solid Financial Position
Compugen reported a strong balance sheet with approximately $103.7 million in cash and no debt, supporting operations into 2027.
CGEN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CGEN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 19, 2025 | $1.39 | $1.39 | 0.00% |
Mar 04, 2025 | $1.81 | $1.68 | -7.18% |
Nov 12, 2024 | $1.74 | $1.60 | -8.05% |
Aug 06, 2024 | $1.64 | $1.72 | +4.88% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Compugen Ltd (CGEN) report earnings?
Compugen Ltd (CGEN) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Compugen Ltd (CGEN) earnings time?
Compugen Ltd (CGEN) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CGEN EPS forecast?
CGEN EPS forecast for the fiscal quarter 2025 (Q2) is -0.06.